• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应变特异性益生菌在心血管疾病管理中的应用:系统评价。

Applications of Strain-Specific Probiotics in the Management of Cardiovascular Diseases: A Systemic Review.

机构信息

Department of Human Nutrition and Dietetics, School of Food and Agricultural Sciences, University of Management and Technology, Lahore, 54000, Pakistan.

Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, 27272, United Arab Emirates.

出版信息

Mol Nutr Food Res. 2024 Apr;68(8):e2300675. doi: 10.1002/mnfr.202300675. Epub 2024 Mar 29.

DOI:10.1002/mnfr.202300675
PMID:38549453
Abstract

Cardiovascular diseases (CVDs) are a leading cause of global mortality and novel approaches for prevention and management are needed. The human gastrointestinal tract hosts a diverse microbiota that is crucial in maintaining metabolic homeostasis. The formulation of effective probiotics, alone or in combination, has been under discussion due to their impact on cardiovascular and metabolic diseases. Probiotics have been shown to impact cardiovascular health positively. An imbalance in the presence of Firmicutes and Bacteroidetes has been linked to the progression of CVDs due to their impact on bile acid and cholesterol metabolism. The probiotics primarily help in the reduction of plasma low-density lipoprotein levels and attenuation of the proinflammatory markers. These beneficial microorganisms contribute to lowering cholesterol levels and produce essential short-chain fatty acids. The impact of lipid-regulating probiotic strains on human health is quite significant. However, only a few have been tested for potential beneficial efficacy, and ambiguity exists regarding strain dosages, interactions with confounding factors, and potential adverse effects. Hence, more comprehensive studies and randomized trials are needed to understand the mechanisms of probiotics on CVDs and to ensure human health. This review assesses the evidence and highlights the roles of strain-specific probiotics in the management of CVDs.

摘要

心血管疾病(CVDs)是全球死亡率的主要原因,因此需要新的预防和管理方法。人类胃肠道中存在着多样化的微生物群,对于维持代谢平衡至关重要。由于其对心血管和代谢疾病的影响,单独或联合使用有效的益生菌制剂一直是讨论的话题。益生菌已被证明对心血管健康有积极影响。由于其对胆汁酸和胆固醇代谢的影响,厚壁菌门和拟杆菌门的存在失衡与 CVD 的进展有关。益生菌主要有助于降低血浆低密度脂蛋白水平,并减轻促炎标志物。这些有益微生物有助于降低胆固醇水平并产生必需的短链脂肪酸。调节脂质的益生菌菌株对人类健康的影响非常显著。然而,只有少数几种益生菌菌株经过了潜在有益功效的测试,其菌株剂量、与混杂因素的相互作用以及潜在的不良反应仍然存在不确定性。因此,需要进行更全面的研究和随机试验,以了解益生菌对 CVD 的作用机制,并确保人类健康。本综述评估了相关证据,并强调了特定菌株益生菌在 CVD 管理中的作用。

相似文献

1
Applications of Strain-Specific Probiotics in the Management of Cardiovascular Diseases: A Systemic Review.应变特异性益生菌在心血管疾病管理中的应用:系统评价。
Mol Nutr Food Res. 2024 Apr;68(8):e2300675. doi: 10.1002/mnfr.202300675. Epub 2024 Mar 29.
2
Circulating bile acids as a link between the gut microbiota and cardiovascular health: impact of prebiotics, probiotics and polyphenol-rich foods.胆汁酸作为肠道微生物群和心血管健康之间的联系:益生元、益生菌和富含多酚的食物的影响。
Nutr Res Rev. 2022 Dec;35(2):161-180. doi: 10.1017/S0954422421000081. Epub 2021 Apr 30.
3
Cardiovascular Diseases of Developmental Origins: Preventive Aspects of Gut Microbiota-Targeted Therapy.发育源性心血管疾病:靶向肠道微生物群的预防治疗策略。
Nutrients. 2021 Jul 1;13(7):2290. doi: 10.3390/nu13072290.
4
Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease.肠道微生物组介导降低胆固醇水平的机制:改善心血管疾病的意义。
Trends Microbiol. 2023 Jan;31(1):76-91. doi: 10.1016/j.tim.2022.08.003. Epub 2022 Aug 22.
5
The influence of the human microbiome and probiotics on cardiovascular health.人类微生物组和益生菌对心血管健康的影响。
Gut Microbes. 2014;5(6):719-28. doi: 10.4161/19490976.2014.983775.
6
Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review).肠道微生物群代谢物作为心血管疾病的重要介质(综述)。
Int J Mol Med. 2020 Sep;46(3):936-948. doi: 10.3892/ijmm.2020.4674. Epub 2020 Jul 13.
7
Probiotics, gut microbiome, and cardiovascular diseases: An update.益生菌、肠道微生物群与心血管疾病:最新进展。
Transpl Immunol. 2024 Apr;83:102000. doi: 10.1016/j.trim.2024.102000. Epub 2024 Jan 21.
8
Bridging the Gap between Gut Microbial Dysbiosis and Cardiovascular Diseases.肠道微生物失调与心血管疾病之间的桥梁。
Nutrients. 2017 Aug 10;9(8):859. doi: 10.3390/nu9080859.
9
The role of intestinal microbiota in cardiovascular disease.肠道微生物群在心血管疾病中的作用。
J Cell Mol Med. 2019 Apr;23(4):2343-2350. doi: 10.1111/jcmm.14195. Epub 2019 Feb 3.
10
Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.益生菌对炎症性肠病中肠道微生物-胆汁酸轴的调节作用。
Front Immunol. 2022 Sep 23;13:974305. doi: 10.3389/fimmu.2022.974305. eCollection 2022.

引用本文的文献

1
Association of the Dietary Index for Gut Microbiota and Cardiovascular-Kidney-Metabolic Syndrome: The Mediation Effect of Phenotypic and Biological Age Acceleration, BMI, and BRI.肠道微生物群饮食指数与心血管-肾脏-代谢综合征的关联:表型和生物学年龄加速、体重指数和身体组成指数的中介作用
Food Sci Nutr. 2025 Sep 7;13(9):e70815. doi: 10.1002/fsn3.70815. eCollection 2025 Sep.
2
Therapeutic effects of medicinal and food-based traditional herbal couples on type 2 diabetes mellitus based on pharmacodynamics and pharmacokinetics.基于药效学和药代动力学的药食同源传统中药药对治疗2型糖尿病的作用
Front Pharmacol. 2025 Apr 25;16:1560271. doi: 10.3389/fphar.2025.1560271. eCollection 2025.
3
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy.
肠道微生物群失调:发病机制、疾病、预防与治疗
MedComm (2020). 2025 Apr 18;6(5):e70168. doi: 10.1002/mco2.70168. eCollection 2025 May.
4
Microbiota modifications in prehabilitation - the next step towards comprehensive preparation for surgery. The scoping review.术前康复中的微生物群改变——迈向手术全面准备的下一步。范围综述。
Prz Gastroenterol. 2024;16(4):347-361. doi: 10.5114/pg.2024.145833. Epub 2024 Dec 11.